



## Product Information

**Product ID** L1817

**CAS No.** 75706-12-6

**Chemical Name** 5-Methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide

**Synonym** HWA-486, Arava

**Formula** C<sub>12</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>

**Formula Wt.** 270.21

**Melting Point** 166.5°C


**Purity** ≥98%

**Solubility** Soluble in DMSO or methanol.

**Store Temp** -20°C

**Ship Temp** Ambient

**Description** Leflunomide inhibits dihydroorotate dehydrogenase, preventing UMP formation and pyrimidine synthesis. Metabolites of leflunomide may inhibit various kinases such as JNK and JAK. Leflunomide is clinically used to treat rheumatoid arthritis; it exhibits immunosuppressive, antiviral, and anticancer activities. In several cellular models, leflunomide prevents apoptosis and increases viability in human cytomegalovirus (CMV)-infected cells and inhibits replication of polyomavirus BK. Additionally, leflunomide increases activity of aryl hydrocarbon receptors, inhibiting proliferation of melanoma cells.



**Bulk quantities available upon request**

Product ID	Size
------------	------

L1817	100 mg
-------	--------

L1817	500 mg
-------	--------

L1817	1 g
-------	-----

**References** Qi R, Hua-Song Z, Xiao-Feng Z. Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. *Eur J Med Res.* 2013 Feb 1;18:3. PMID: 23369524.

O'Donnell EF, Kopparapu PR, Koch DC, et al. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. *PLoS One.* 2012;7(7):e40926. PMID: 22815870.

Bernhoff E, Tylden GD, Kjerpeseth LJ, et al. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. *J Virol.* 2010 Feb;84(4):2150-6. PMID: 19955306.

Pinto P, Dougados M. Leflunomide in clinical practice. *Acta Reumatol Port.* 2006 Jul-Sep;31(3):215-24. PMID: 17094333.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.